Intratumor heterogeneity for EGFR mutation has been proven to exist by the analysis of different areas of a single NSCLC tumor [23], and further evidence of this heterogeneity stems from the predictive benefit of EGFR-TKI treatment from the relative abundance of EGFR mutations [24]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.